培美曲塞致皮肤色素沉着与肺腺癌化疗疗效关系的研究  

The relationship between pemetrexed-induced skin pigmentation and the efficacy of chemotherapy for lung adenocarcinoma

作　　者：张琰[1] 陶洁[1] 王莹[2] Yan Zhang;Jie Tao;Ying Wang(Department of PulmonaryMedicine,Affiliated Tumor Hospital of XinjiangMedical University,Urumqi 830011,China;Medical Department,Affiliated Tumor Hospital of XinjiangMedical University,Urumqi 830011,China)

机构地区：[1]新疆医科大学附属肿瘤医院肺内科一病区,乌鲁木齐市830011 [2]新疆医科大学附属肿瘤医院医务部,乌鲁木齐市830011

出　　处：《中国肿瘤临床》2021年第8期392-394,共3页Chinese Journal of Clinical Oncology

基　　金：新疆维吾尔自治区自然科学基金(编号:2017D01C399)资助。

摘　　要：目的:探讨晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)中肺腺癌患者使用培美曲塞化疗出现色素沉着及其与临床病理特征、培美曲塞化疗疗效的相关性。方法:收集新疆医科大学附属肿瘤医院2016年1月至2018年12月经组织病理证实为肺腺癌患者117例,采用不良事件的通用术语标准(CTCAE)4.0版对因使用培美曲塞出现皮肤色素沉着不良反应进行分级,并结合临床病理特征、培美曲塞的化疗疗效进行分析。结果:皮肤色素沉着发生率为43.6%(51/117),不同年龄、性别、肿瘤分期、肿瘤分化程度及吸烟情况的晚期肺腺癌患者的皮肤色素沉着发生率差异无统计学意义(P>0.05);出现皮肤色素沉着的患者与未出现皮肤色素沉着的患者相比,化疗有效率更高(47.1%vs.24.2%,P<0.05);出现皮肤色素沉着的患者无进展生存期(progression-free survival,PFS)显著长于未出现皮肤色素沉着的患者(6.2个月vs.4.1个月,P<0.05)。结论:培美曲塞治疗后出现皮肤色素沉着的患者有效率更高,皮肤色素沉着可能成为培美曲塞治疗晚期NSCLC的预后指标。Objective:To investigate the relationship between pigmentation and clinicopathological features and the therapeutic effect of pemetrexed in patients with lung adenocarcinoma in advanced non-small cell lung cancer(NSCLC).Methods:A total of 117 patients with lung adenocarcinoma,confirmed by histopathology studies conducted from January 2016 to December 2018 at Affiliated Tumor Hospital of Xinjiang Medical University,were recruited.The adverse reaction of skin pigmentation caused by pemetrexed was graded using Common Terminology Criteria for Adverse Events(CTCAE)version 4.0,and the clinicopathological characteristics and efficacy of pemetrexed in hemotherapy were analyzed.Result:The overall incidence of skin pigmentation was 43.6%.There was no significant difference in skin pigmentation with respect to age,sex,tumor stage,tumor differentiation degree,and smoking history(P>0.05).The efficacy rate of chemotherapy in patients with skin pigmentation was significantly higher(P<0.05)when compared to that in those without skin pigmentation.The progression-free survival(PFS)in patients with skin pigmentation was longer when compared to that in patients without skin pigmentation(6.2 months vs.4.1 months,P<0.05).Conclusions:The efficacy rate of chemotherapy in patients with skin pigmentation was higher than that in those without skin pigmentation.Skin pigmentation may become prognostic indicators in advanced NSCLC treated with pemetrexed.

关 键 词：肺腺癌 培美曲塞 皮肤色素沉着 

分 类 号：R734.2[医药卫生—肿瘤]